Optimal design for multivariate response pharmacokinetic models

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 33, Issue 2, 2006, Pages 97-124

  Gueorguieva, Ivelina ^a,c   Aarons, Leon ^a   Ogungbenro, Kayode ^a   Jorga, Karin M ^b   Rodgers, Trudy ^a   Rowland, Malcolm ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

Beta blockers; D optimal design; Multiresponse situations; Multivariate response; Pharmacokinetic parameters; Physiologically based pharmacokinetic models; Tolcapone

Indexed keywords

ACEBUTOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BISOPROLOL; DRUG METABOLITE; METOPROLOL; OXPRENOLOL; PINDOLOL; PROPRANOLOL; TIMOLOL; TOLCAPONE;

ALGORITHM; ANIMAL EXPERIMENT; ARTICLE; DRUG DISPOSITION; EXPERIMENTAL DESIGN; EXPERIMENTAL MODEL; HUMAN; METHODOLOGY; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RAT; RETROSPECTIVE STUDY; SAMPLING; SIMULATION;

ADRENERGIC BETA-ANTAGONISTS; ALGORITHMS; ANIMALS; ANTIPARKINSON AGENTS; BENZOPHENONES; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MODELS, BIOLOGICAL; MULTIVARIATE ANALYSIS; NITROPHENOLS; PHARMACOKINETICS; RATS; SOFTWARE; TISSUE DISTRIBUTION;

EID: 33645817934     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10928-006-9009-1     Document Type: Article

References (37)

1. W. G. Cochran. Experiments for nonlinear functions. J. Am. Stat. Assoc. 68:771-781 (1973).
2. A. C. Atkinson. Recent developments in the methods of optimum and related experimental designs. Int. Stat. Rev. 56:99-115 (1988).
3. I. Ford, D. M. Tittrington, and C. P. Kitos. Recent advances in nonlinear experimental design. Technometrics 31:49-60 (1989).
4. A. C. Atkinson and A. N. Donev. Optimum Experimental Designs, Oxford Statistical Science Series, vol. 8, Clarendon Press, Oxford, 1992.
5. H. Chernoff. Locally optimal designs for estimating parameters. Ann. Math. Stat. 24:771-781 (1953).
6. D. D'Argenio. Optimal sampling times for pharmacokinetic experiments. J. Pharmacokinet. Biopharm. 9:739-756 (1981).
7. S. Retout, S. Duffull, and F. Mentré. Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs. Comput. Methods Programs Biomed. 65:141-151 (2001).
8. S. Duffull, S. Retout and F. Mentré. The use of simulated annealing for finding optimal population designs. Compu, Methods Programs Biomed. 69:25-35 (2002).
9. S. Retout and F. Mentré. Further developments of the Fisher information matrix in nonlinear mixed effects models with evaluation in population Pharmacokinetics. J. Biopharm. Stat. 13:209-227 (2003).
10. E. Ette, C. A. Howie, A. W. Kelman, and B. Whitting. Experimental design and efficient parameter estimation in preclinical studies. Pharm. Res. 12:729-737 (1995).
11. D. A. Beatty and W. W. Piegorsch. Optimal statistical design for toxicokinetic studies. Stat. Methods Med. Res. 6:359-376 (1997).
12. N. R. Draper and W. G. Hunter. Design of experiments for parameter estimation in multiresponse situations. Biometrika 53:525-533 (1966).
13. C. Hatzis and K. Larntz. Optimal design in nonlinear multiresponse estimation: Poisson model for filter feeding. Biometrics 48:1235-1248 (1966).
14. V. V. Fedorov. Theory of Optimal Experiments, Academic Press, London, 1972.
15. G. Graham, I. Gueorguieva, and K. Dickens. A program for the optimum design of Pharmacokinetic, pharmacodynamic, drug metabolism and drug-drug interaction models. Computh. Methods Programs Biomed. 78:237-249 (2005).
16. F. Mentré, A. Mallet, and D. Baccar. Optimal design in random-effects regression models. Biometrika 84:429-442 (1997).
17. D. D'Argenio and K. Park. Uncertain Pharmacokinetic/pharmacodynamic systems: Design, estimation and control. Control Eng. Pract. 5:1707-1716 (1997).
18. C. Peloquin, G. Jaresko, C. Yong, A. Keung, A. Bulpitt, and R. Jelliffe. Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. Antimicrobial Agents Chemother. 41:2670-2679 (1997).
19. J. A. Nelder and R. Mead. A simplex method for function minimization. Comput. J. 7:308-313 (1965).
20. A. Corana, M. Marchesi, C. Martini, and S. Ridela. Minimizing multimodal function of continuos variables with the Simulated annealing algorithm. ACM Transact. Math. Softw 13:262-280 (1987).
21. L. Pronzato and E. Walter. A general purpose global optimizer: Implementation and applications. Math. Comput. Simulation 26:412-422 (1984).
22. S. F. Masri and G. A. Bekey. A global optimization algorithm using adaptive random search. Appl. Math. Comput. 7:353-375 (1980).
23. K. Ogungbenro, I. Gueorguieva, G. Graham and L. Aarons. The use of modified Fedorov exchange algorithm in optimising sampling times for population pharmacokinetic experiments. Comput. Methods. Programs Biomed. 80:115-125 (2005).
24. W. L. Goffe, G. D. Ferrier, and J. Rogers. Global optimization of statistical functions with simulated annealing. J. Econom. 60:65-99 (1994).
25. G. E. P. Box and H. L. Lucas. Design of experiments in nonlinear situations. Biometrika 46:77-90 (1959).
26. L. Endrenyi. Design of experiments for estimating enzyme and Pharmacokinetic parameters in kinetic data analysis. Design and Analysis of Enzyme and pharmacokinetic Experiments, Plenum, New York, 1981, pp. 137-167.
27. K. Jorga, B. Fotteler, P. Heizmann, and R. Gasser. Metabolism and excretion of tolcapone, a novel inhibitor of catechol-O-methyltransferase. Br. J. Clin. Pharmacol. 48:513-520 (1999).
28. K. M. Jorga, J. M. Kroodsma, B. Fotteler, P. Heizmann, J. Meyer, M. Rasch, and J. Hattum. Effect of liver impairment on the Pharmacokinetic of tolcapone and its metabolites. Clin. Pharmacol. Ther. 63:646-654 (1998).
29. S. L. Beal and L. B. Sheiner. NONMEM User's Guide, University of California, San Franscisco, 1992.
30. P. Goldsmith. Development of a stereochemical physiologically based Pharmacokinetic model of three beta adrenergic antagonists. PhD thesis, University of Manchester, Manchester, UK, 1998.
31. T. Rodgers, D. Leahy, and M. Rowland. Tissue distribution of basic drugs: Accounting for enantiomeric, compound and regional differences among β-blocking drugs in rats. J. Pharmaceuti, Sci. 94:1237-1248 (2005).
32. A. C. Atkinson. Horwitz's rule, transforming both sides and the design of experiments for mechanistic models. J. R. Star. Soc. Ser. C 52:261-278 (2003).
33. R. J. Carroll and D. Ruppert. Transformations and Weighting in Regression. Chapman and Hall, London, 1988.
34. I. Gueorguieva, I. Nestorov, and M. Rowland. Fuzzy simulation of Pharmacokinetic models: Case study of whole body physiologically based model of diazepam. J. Pharmacokinet. Pharmacodyn 31:185-213 (2004).
35. E. Kreyszig. Advanced Engineering Mathematics, 8th edn., Wiley, New York, 1999, p.859.
36. L. Zhang, S. L. Beal, and L. B. Sheiner. Simultaneous vs sequential analysis for population PK/PD data II: Robustness of methods. J. Pharmacokinet. Pharmacodyn. 30:387-404 (2003).
37. L. Zhang, S. L. Beal, and L. B. Sheiner. Simultaneous vs sequential analysis for population PK/PD data I: Best-case performance. J. Pharmacokinet. Pharmacodyn. 30:405-416 (2003).